USPTO ' s Lax Policy Leads to Biologic Formulation Thicket

Bernard Chao (University of Denver), USPTO ' s Lax Policy Leads to Biologic Formulation Thicket (2023): Biosimilar drugs enter the United States market well after they enter the European market. That is likely due to high patent assertion rates in the U.S....

Source: HealthLawProf Blog - February 20, 2023 Category: Medical Law Authors: Katharine Van Tassel Source Type: blogs